{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:37:06Z","timestamp":1768955826301,"version":"3.49.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11473-y","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T11:50:58Z","timestamp":1768909858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug resistance in chronic myeloid leukemia: the involvement of Galectin-1 and Galectin-3"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9015-6636","authenticated-orcid":false,"given":"Cansu","family":"Y\u0131ld\u0131r\u0131m","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"11473_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cytogfr.2025.05.001","volume":"83","author":"T Shammas","year":"2025","unstructured":"Shammas T, Peiris MN, Meyer AN, Donoghue DJ (2025) BCR-ABL: the molecular mastermind behind chronic myeloid leukemia. Cytokine Growth Factor Rev 83:45\u201358. https:\/\/doi.org\/10.1016\/j.cytogfr.2025.05.001","journal-title":"Cytokine Growth Factor Rev"},{"key":"11473_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.7150\/ijbs.86305","volume":"20","author":"J Sun","year":"2024","unstructured":"Sun J, Hu R, Han M et al (2024) Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia. Int J Biol Sci 20:175\u2013181. https:\/\/doi.org\/10.7150\/ijbs.86305","journal-title":"Int J Biol Sci"},{"key":"11473_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/164_2023_639","volume":"280","author":"M Kaehler","year":"2023","unstructured":"Kaehler M, Cascorbi I (2023) Molecular mechanisms of tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Handb Exp Pharmacol 280:65\u201383. https:\/\/doi.org\/10.1007\/164_2023_639","journal-title":"Handb Exp Pharmacol"},{"key":"11473_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/MOH.0b013e328362370f","volume":"20","author":"M Giordano","year":"2013","unstructured":"Giordano M, Croci DO, Rabinovich GA (2013) Galectins in hematological malignancies. Curr Opin Hematol 20:327\u2013335. https:\/\/doi.org\/10.1097\/MOH.0b013e328362370f","journal-title":"Curr Opin Hematol"},{"key":"11473_CR5","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1182\/blood.2024026312","volume":"145","author":"N Cruz-Rodriguez","year":"2025","unstructured":"Cruz-Rodriguez N, Deininger MW (2025) Novel treatment strategies for chronic myeloid leukemia. Blood 145:931\u2013943. https:\/\/doi.org\/10.1182\/blood.2024026312","journal-title":"Blood"},{"key":"11473_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/17474086.2024.2440776","volume":"18","author":"A Lagan\u00e0","year":"2025","unstructured":"Lagan\u00e0 A, Scalzulli E, Bisegna ML et al (2025) Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Expert Rev Hematol 18:65\u201379. https:\/\/doi.org\/10.1080\/17474086.2024.2440776","journal-title":"Expert Rev Hematol"},{"key":"11473_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejphar.2018.11.019","volume":"844","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Feng W, Wang Y-J et al (2019) Galectins as potential emerging key targets in different types of leukemia. Eur J Pharmacol 844:73\u201378. https:\/\/doi.org\/10.1016\/j.ejphar.2018.11.019","journal-title":"Eur J Pharmacol"},{"key":"11473_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jbior.2018.09.003","volume":"71","author":"PP Ruvolo","year":"2019","unstructured":"Ruvolo PP (2019) Galectins as regulators of cell survival in the leukemia niche. Adv Biol Regul 71:41\u201354. https:\/\/doi.org\/10.1016\/j.jbior.2018.09.003","journal-title":"Adv Biol Regul"},{"key":"11473_CR9","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2305-5839.2014.09.14","volume":"2","author":"C Pena","year":"2014","unstructured":"Pena C, Mirandola L, Figueroa JA et al (2014) Galectins as therapeutic targets for hematological malignancies: a hopeful sweetness. Ann Transl Med 2:87. https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2014.09.14","journal-title":"Ann Transl Med"},{"key":"11473_CR10","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s11033-024-09563-w","volume":"51","author":"C Y\u0131ld\u0131r\u0131m","year":"2024","unstructured":"Y\u0131ld\u0131r\u0131m C (2024) Galectin-9, a pro-survival factor inducing immunosuppression, leukemic cell transformation and expansion. Mol Biol Rep 51:571. https:\/\/doi.org\/10.1007\/s11033-024-09563-w","journal-title":"Mol Biol Rep"},{"key":"11473_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/life15060937","author":"C Y\u0131ld\u0131r\u0131m","year":"2025","unstructured":"Y\u0131ld\u0131r\u0131m C (2025) Galectin-3 release in the bone marrow microenvironment promotes drug resistance and relapse in acute myeloid leukemia. Life (Basel). https:\/\/doi.org\/10.3390\/life15060937","journal-title":"Life (Basel)"},{"key":"11473_CR12","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2174\/138161282005140214165212","volume":"20","author":"YH Choi","year":"2014","unstructured":"Choi YH, Yu A-M (2014) ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des 20:793\u2013807. https:\/\/doi.org\/10.2174\/138161282005140214165212","journal-title":"Curr Pharm Des"},{"key":"11473_CR13","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","volume":"101","author":"F-X Mahon","year":"2003","unstructured":"Mahon F-X, Belloc F, Lagarde V et al (2003) MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101:2368\u201373. https:\/\/doi.org\/10.1182\/blood.V101.6.2368","journal-title":"Blood"},{"key":"11473_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/sj.leu.2403257","volume":"18","author":"T Illmer","year":"2004","unstructured":"Illmer T, Schaich M, Platzbecker U et al (2004) P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18:401\u20138. https:\/\/doi.org\/10.1038\/sj.leu.2403257","journal-title":"Leukemia"},{"key":"11473_CR15","doi-asserted-by":"publisher","first-page":"26709","DOI":"10.18632\/oncotarget.8489","volume":"7","author":"W Luo","year":"2016","unstructured":"Luo W, Song L, Chen X-L et al (2016) Identification of galectin-1 as a novel mediator for chemoresistance in chronic myeloid leukemia cells. Oncotarget 7:26709\u201323. https:\/\/doi.org\/10.18632\/oncotarget.8489","journal-title":"Oncotarget"},{"key":"11473_CR16","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/glycob\/7.8.1193","volume":"7","author":"D Lutomski","year":"1997","unstructured":"Lutomski D, Fouillit M, Bourin P et al (1997) Externalization and binding of galectin-1 on cell surface of K562 cells upon erythroid differentiation. Glycobiology 7:1193\u20131199. https:\/\/doi.org\/10.1093\/glycob\/7.8.1193","journal-title":"Glycobiology"},{"key":"11473_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.779567","author":"M-Y Li","year":"2021","unstructured":"Li M-Y, Zhao C, Chen L et al (2021) Quantitative proteomic analysis of plasma exosomes to identify the candidate biomarker of imatinib resistance in chronic myeloid leukemia patients. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2021.779567","journal-title":"Front Oncol"},{"key":"11473_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-025-01047-8","volume":"47","author":"J Nov\u00e1k","year":"2025","unstructured":"Nov\u00e1k J, Tak\u00e1cs T, Tilajka \u00c1 et al (2025) The sweet and the bitter sides of galectin-1 in immunity: its role in immune cell functions, apoptosis, and immunotherapies for cancer with a focus on T cells. Semin Immunopathol 47:24. https:\/\/doi.org\/10.1007\/s00281-025-01047-8","journal-title":"Semin Immunopathol"},{"key":"11473_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/sj.onc.1206056","volume":"22","author":"M Bentires-Alj","year":"2003","unstructured":"Bentires-Alj M, Barbu V, Fillet M et al (2003) NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22:90\u201397. https:\/\/doi.org\/10.1038\/sj.onc.1206056","journal-title":"Oncogene"},{"key":"11473_CR20","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1091\/mbc.e07-10-1053","volume":"19","author":"L Belanis","year":"2008","unstructured":"Belanis L, Plowman SJ, Rotblat B et al (2008) Galectin-1 is a novel structural component and a major regulator of h-ras nanoclusters. Mol Biol Cell 19:1404\u201314. https:\/\/doi.org\/10.1091\/mbc.e07-10-1053","journal-title":"Mol Biol Cell"},{"key":"11473_CR21","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1158\/1078-0432.CCR-11-3348","volume":"18","author":"L-Y Chung","year":"2012","unstructured":"Chung L-Y, Tang S-J, Sun G-H et al (2012) Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2. Clin Cancer Res 18:4037\u20134047. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-3348","journal-title":"Clin Cancer Res"},{"key":"11473_CR22","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41375-022-01789-6","volume":"37","author":"K Li","year":"2023","unstructured":"Li K, Du Y, Cai Y et al (2023) Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed\/refractory acute myeloid leukemia. Leukemia 37:308\u2013325. https:\/\/doi.org\/10.1038\/s41375-022-01789-6","journal-title":"Leukemia"},{"key":"11473_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114835","volume":"158","author":"L Liu","year":"2025","unstructured":"Liu L, Cheng P, Cui J et al (2025) Galectin-1: an important regulator in myeloid differentiation and acute myeloid leukemia as well as a promising prognostic indicator and therapeutic target. Int Immunopharmacol 158:114835. https:\/\/doi.org\/10.1016\/j.intimp.2025.114835","journal-title":"Int Immunopharmacol"},{"key":"11473_CR24","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1625015","volume":"2016","author":"P Sontakke","year":"2016","unstructured":"Sontakke P, Jaques J, Vellenga E, Schuringa JJ (2016) Modeling of chronic myeloid leukemia: an overview of in vivo murine and human xenograft models. Stem Cells Int 2016:1625015. https:\/\/doi.org\/10.1155\/2016\/1625015","journal-title":"Stem Cells Int"},{"key":"11473_CR25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s13402-024-01003-y","volume":"48","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Zhang D, He X et al (2025) BCAT1 contributes to the development of TKI-resistant CML. Cell Oncol 48:411\u2013424. https:\/\/doi.org\/10.1007\/s13402-024-01003-y","journal-title":"Cell Oncol"},{"key":"11473_CR26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41388-022-02536-y","volume":"42","author":"D Ma","year":"2023","unstructured":"Ma D, Liu P, Hu C et al (2023) Intracellular angiopoietin-1 promotes TKI-resistance via activation of JAK\/STAT5 pathway in chronic myeloid leukemia. Oncogene 42:124\u2013137. https:\/\/doi.org\/10.1038\/s41388-022-02536-y","journal-title":"Oncogene"},{"key":"11473_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cells14191565","volume":"14","author":"KA Turner","year":"2025","unstructured":"Turner KA, Chen M, Rothe K et al (2025) Dual targeting of smoothened, a key regulator in the hedgehog pathway, and BCR-ABL1 effectively eradicates drug-insensitive stem\/progenitor cells in chronic myeloid leukemia. Cells 14:1565. https:\/\/doi.org\/10.3390\/cells14191565","journal-title":"Cells"},{"key":"11473_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01080-3","volume":"15","author":"J Bai","year":"2024","unstructured":"Bai J, Feng Z, Chen Y et al (2024) Lycorine attenuated proliferation and induced apoptosis on imatinib-resistant K562 cell by inhibiting autophagy. Discov Oncol 15:217. https:\/\/doi.org\/10.1007\/s12672-024-01080-3","journal-title":"Discov Oncol"},{"key":"11473_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-025-01921-0","volume":"17","author":"H Yang","year":"2025","unstructured":"Yang H, Li V, Park SJ et al (2025) Martinostat as a novel HDAC inhibitor to overcome tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Clin Epigenetics 17:125. https:\/\/doi.org\/10.1186\/s13148-025-01921-0","journal-title":"Clin Epigenetics"},{"key":"11473_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06865-6","volume":"15","author":"H Qin","year":"2024","unstructured":"Qin H, Peng M, Cheng J et al (2024) A novel LGALS1-depended and immune-associated fatty acid metabolism risk model in acute myeloid leukemia stem cells. Cell Death Dis 15:482. https:\/\/doi.org\/10.1038\/s41419-024-06865-6","journal-title":"Cell Death Dis"},{"key":"11473_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17183033","author":"M Tolland","year":"2025","unstructured":"Tolland M, Ross DM, White D et al (2025) Lipid storage and therapy resistance in chronic myeloid leukaemia: a novel perspective on targeting metabolic vulnerabilities. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17183033","journal-title":"Cancers (Basel)"},{"key":"11473_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03805-y","volume":"25","author":"C Mancini","year":"2025","unstructured":"Mancini C, Menegazzi G, Peppicelli S et al (2025) BCR::ABL1 expression in chronic myeloid leukemia cells in low oxygen is regulated by glutamine via CD36-mediated fatty acid uptake. Cancer Cell Int 25:176. https:\/\/doi.org\/10.1186\/s12935-025-03805-y","journal-title":"Cancer Cell Int"},{"key":"11473_CR33","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1182\/blood-2012-07-443762","volume":"121","author":"C-L Cheng","year":"2013","unstructured":"Cheng C-L, Hou H-A, Lee M-C et al (2013) Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. Blood 121:3172\u20133180. https:\/\/doi.org\/10.1182\/blood-2012-07-443762","journal-title":"Blood"},{"key":"11473_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-014-0099-8","volume":"8","author":"K Hu","year":"2015","unstructured":"Hu K, Gu Y, Lou L et al (2015) Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt\/\u03b2-catenin signaling pathway. J Hematol Oncol 8:1. https:\/\/doi.org\/10.1186\/s13045-014-0099-8","journal-title":"J Hematol Oncol"},{"key":"11473_CR35","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.bbrc.2011.07.099","volume":"412","author":"Y-L Cheng","year":"2011","unstructured":"Cheng Y-L, Huang W-C, Chen C-L et al (2011) Increased galectin-3 facilitates leukemia cell survival from apoptotic stimuli. Biochem Biophys Res Commun 412:334\u201340. https:\/\/doi.org\/10.1016\/j.bbrc.2011.07.099","journal-title":"Biochem Biophys Res Commun"},{"key":"11473_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.canlet.2011.09.003","volume":"313","author":"AU Newlaczyl","year":"2011","unstructured":"Newlaczyl AU, Yu L-G (2011) Galectin-3\u2013a jack-of-all-trades in cancer. Cancer Lett 313:123\u2013128. https:\/\/doi.org\/10.1016\/j.canlet.2011.09.003","journal-title":"Cancer Lett"},{"key":"11473_CR37","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10495-005-0801-y","volume":"10","author":"S Nakahara","year":"2005","unstructured":"Nakahara S, Oka N, Raz A (2005) On the role of galectin-3 in cancer apoptosis. Apoptosis 10:267\u201375. https:\/\/doi.org\/10.1007\/s10495-005-0801-y","journal-title":"Apoptosis"},{"key":"11473_CR38","doi-asserted-by":"publisher","first-page":"4395","DOI":"10.1128\/MCB.24.10.4395-4406.2004","volume":"24","author":"Y Takenaka","year":"2004","unstructured":"Takenaka Y, Fukumori T, Yoshii T et al (2004) Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol 24:4395\u2013406. https:\/\/doi.org\/10.1128\/MCB.24.10.4395-4406.2004","journal-title":"Mol Cell Biol"},{"key":"11473_CR39","doi-asserted-by":"publisher","first-page":"7527","DOI":"10.1038\/sj.onc.1207997","volume":"23","author":"S Califice","year":"2004","unstructured":"Califice S, Castronovo V, Bracke M, van den Br\u00fble F (2004) Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 23:7527\u201336. https:\/\/doi.org\/10.1038\/sj.onc.1207997","journal-title":"Oncogene"},{"key":"11473_CR40","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1158\/0008-5472.CAN-05-3750","volume":"66","author":"T Fukumori","year":"2006","unstructured":"Fukumori T, Oka N, Takenaka Y et al (2006) Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res 66:3114\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-3750","journal-title":"Cancer Res"},{"key":"11473_CR41","doi-asserted-by":"publisher","first-page":"15819","DOI":"10.1074\/jbc.M200154200","volume":"277","author":"F Yu","year":"2002","unstructured":"Yu F, Finley RL, Raz A, Kim H-RC (2002) Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for Synexin in galectin-3 translocation. J Biol Chem 277:15819\u201315827. https:\/\/doi.org\/10.1074\/jbc.M200154200","journal-title":"J Biol Chem"},{"key":"11473_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.985363","author":"S Qian","year":"2022","unstructured":"Qian S, Wei Z, Yang W et al (2022) The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2022.985363","journal-title":"Front Oncol"},{"key":"11473_CR43","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.bbamcr.2015.12.008","volume":"1863","author":"PP Ruvolo","year":"2016","unstructured":"Ruvolo PP, Ruvolo VR, Benton CB et al (2016) Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1863:562\u2013571. https:\/\/doi.org\/10.1016\/j.bbamcr.2015.12.008","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"key":"11473_CR44","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s10555-013-9450-8","volume":"33","author":"Y Harazono","year":"2014","unstructured":"Harazono Y, Nakajima K, Raz A (2014) Why anti-Bcl-2 clinical trials fail: a solution. Cancer Metastasis Rev 33:285\u201394. https:\/\/doi.org\/10.1007\/s10555-013-9450-8","journal-title":"Cancer Metastasis Rev"},{"key":"11473_CR45","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10863-006-9063-9","volume":"39","author":"P Nangia-Makker","year":"2007","unstructured":"Nangia-Makker P, Nakahara S, Hogan V, Raz A (2007) Galectin-3 in apoptosis, a novel therapeutic target. J Bioenerg Biomembr 39:79\u201384. https:\/\/doi.org\/10.1007\/s10863-006-9063-9","journal-title":"J Bioenerg Biomembr"},{"key":"11473_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-144","volume":"9","author":"R Mishra","year":"2010","unstructured":"Mishra R (2010) Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol Cancer 9:144. https:\/\/doi.org\/10.1186\/1476-4598-9-144","journal-title":"Mol Cancer"},{"key":"11473_CR47","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.bbagen.2005.12.020","volume":"1760","author":"J Dumic","year":"2006","unstructured":"Dumic J, Dabelic S, Fl\u00f6gel M (2006) Galectin-3: an open-ended story. Biochimica et Biophysica Acta (BBA) - General Subjects 1760:616\u2013635. https:\/\/doi.org\/10.1016\/j.bbagen.2005.12.020","journal-title":"Biochimica et Biophysica Acta (BBA) - General Subjects"},{"key":"11473_CR48","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1038\/sj.bjc.6605437","volume":"101","author":"V Bilim","year":"2009","unstructured":"Bilim V, Ougolkov A, Yuuki K et al (2009) Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. Br J Cancer 101:2005\u201314. https:\/\/doi.org\/10.1038\/sj.bjc.6605437","journal-title":"Br J Cancer"},{"key":"11473_CR49","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood-2006-12-060947","volume":"110","author":"AV Ougolkov","year":"2007","unstructured":"Ougolkov AV, Bone ND, Fernandez-Zapico ME et al (2007) Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor \u03baB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 110:735\u201342. https:\/\/doi.org\/10.1182\/blood-2006-12-060947","journal-title":"Blood"},{"key":"11473_CR50","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/nature07284","volume":"455","author":"Z Wang","year":"2008","unstructured":"Wang Z, Smith KS, Murphy M et al (2008) Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 455:1205\u20139. https:\/\/doi.org\/10.1038\/nature07284","journal-title":"Nature"},{"key":"11473_CR51","doi-asserted-by":"publisher","first-page":"17468","DOI":"10.1073\/pnas.1111138108","volume":"108","author":"M Yamamoto-Sugitani","year":"2011","unstructured":"Yamamoto-Sugitani M, Kuroda J, Ashihara E et al (2011) Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Natl Acad Sci U S A 108:17468\u201373. https:\/\/doi.org\/10.1073\/pnas.1111138108","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11473_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232214359","volume":"23","author":"F Fei","year":"2022","unstructured":"Fei F, Zhang M, Tarighat SS et al (2022) Galectin-1 and Galectin-3 in B-Cell Precursor Acute Lymphoblastic Leukemia. Int J Mol Sci 23:14359. https:\/\/doi.org\/10.3390\/ijms232214359","journal-title":"Int J Mol Sci"},{"key":"11473_CR53","doi-asserted-by":"publisher","first-page":"11378","DOI":"10.18632\/oncotarget.3409","volume":"6","author":"F Fei","year":"2015","unstructured":"Fei F, Joo EJ, Tarighat SS et al (2015) B-cell precursor acute lymphoblastic leukemia and stromal cells communicate through Galectin-3. Oncotarget 6:11378\u201394. https:\/\/doi.org\/10.18632\/oncotarget.3409","journal-title":"Oncotarget"},{"key":"11473_CR54","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1038\/leu.2013.175","volume":"27","author":"F Fei","year":"2013","unstructured":"Fei F, Abdel-Azim H, Lim M et al (2013) Galectin-3 in pre-B acute lymphoblastic leukemia. Leukemia 27:2385\u20138. https:\/\/doi.org\/10.1038\/leu.2013.175","journal-title":"Leukemia"},{"key":"11473_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212167","volume":"22","author":"SS Tarighat","year":"2021","unstructured":"Tarighat SS, Fei F, Joo EJ et al (2021) Overcoming Microenvironment-Mediated Chemoprotection through Stromal Galectin-3 Inhibition in Acute Lymphoblastic Leukemia. Int J Mol Sci 22:12167. https:\/\/doi.org\/10.3390\/ijms222212167","journal-title":"Int J Mol Sci"},{"key":"11473_CR56","doi-asserted-by":"publisher","first-page":"810","DOI":"10.3324\/haematol.2017.172429","volume":"103","author":"SM Kornblau","year":"2018","unstructured":"Kornblau SM, Ruvolo PP, Wang R-Y et al (2018) Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival. Haematologica 103:810\u2013821. https:\/\/doi.org\/10.3324\/haematol.2017.172429","journal-title":"Haematologica"},{"key":"11473_CR57","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.37349\/etat.2024.00262","volume":"5","author":"S Khattab","year":"2024","unstructured":"Khattab S, El Sorady M, El-Ghandour A et al (2024) Hematopoietic and leukemic stem cells homeostasis: the role of bone marrow niche. Explor Target Antitumor Ther 5:1027\u20131055. https:\/\/doi.org\/10.37349\/etat.2024.00262","journal-title":"Explor Target Antitumor Ther"},{"key":"11473_CR58","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.molcel.2006.02.009","volume":"21","author":"U Maurer","year":"2006","unstructured":"Maurer U, Charvet C, Wagman AS et al (2006) Glycogen Synthase Kinase-3 Regulates Mitochondrial Outer Membrane Permeabilization and Apoptosis by Destabilization of MCL-1. Mol Cell 21:749\u2013760. https:\/\/doi.org\/10.1016\/j.molcel.2006.02.009","journal-title":"Mol Cell"},{"key":"11473_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047060","volume":"7","author":"SK Nifoussi","year":"2012","unstructured":"Nifoussi SK, Vrana JA, Domina AM et al (2012) Thr 163 Phosphorylation Causes Mcl-1 Stabilization when Degradation Is Independent of the Adjacent GSK3-Targeted Phosphodegron, Promoting Drug Resistance in Cancer. PLoS One 7:e47060. https:\/\/doi.org\/10.1371\/journal.pone.0047060","journal-title":"PLoS One"},{"key":"11473_CR60","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ebiom.2019.05.025","volume":"44","author":"PP Ruvolo","year":"2019","unstructured":"Ruvolo PP, Hu CW, Qiu Y et al (2019) LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML. EBioMedicine 44:126\u2013137. https:\/\/doi.org\/10.1016\/j.ebiom.2019.05.025","journal-title":"EBioMedicine"},{"key":"11473_CR61","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1002\/ijc.25946","volume":"129","author":"T Kobayashi","year":"2011","unstructured":"Kobayashi T, Shimura T, Yajima T et al (2011) Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of \u03b2\u2010catenin. Int J Cancer 129:2775\u20132786. https:\/\/doi.org\/10.1002\/ijc.25946","journal-title":"Int J Cancer"},{"key":"11473_CR62","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1158\/0008-5472.CAN-08-4153","volume":"69","author":"S Song","year":"2009","unstructured":"Song S, Mazurek N, Liu C et al (2009) Galectin-3 mediates nuclear \u03b2-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3\u03b2 activity. Cancer Res 69:1343\u20131349. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-4153","journal-title":"Cancer Res"},{"key":"11473_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00532","author":"S Grassi","year":"2019","unstructured":"Grassi S, Palumbo S, Mariotti V et al (2019) The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2019.00532","journal-title":"Front Oncol"},{"key":"11473_CR64","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1182\/blood-2014-06-583062","volume":"125","author":"S Krause","year":"2015","unstructured":"Krause S, Pfeiffer C, Strube S et al (2015) Mer tyrosine kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS). Blood 125:820\u201330. https:\/\/doi.org\/10.1182\/blood-2014-06-583062","journal-title":"Blood"},{"key":"11473_CR65","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-03632-7","volume":"16","author":"M Yousaf","year":"2025","unstructured":"Yousaf M, Arif K, Khan D (2025) TAM family kinases are potential candidate targets for therapeutic intervention in chronic myeloid leukemia. Discov Oncol 16:1944. https:\/\/doi.org\/10.1007\/s12672-025-03632-7","journal-title":"Discov Oncol"},{"key":"11473_CR66","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.leukres.2013.07.026","volume":"38","author":"R Nakayama","year":"2014","unstructured":"Nakayama R, Kuroda J, Taniyama N et al (2014) Suppression of SERPINA1-albumin complex formation by galectin-3 overexpression leads to paracrine growth promotion of chronic myelogenous leukemia cells. Leuk Res 38:103\u2013108. https:\/\/doi.org\/10.1016\/j.leukres.2013.07.026","journal-title":"Leuk Res"},{"key":"11473_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cccn.2004.03.012","volume":"352","author":"B Lisowska-Myjak","year":"2005","unstructured":"Lisowska-Myjak B (2005) AAT as a diagnostic tool. Clin Chim Acta 352:1\u201313. https:\/\/doi.org\/10.1016\/j.cccn.2004.03.012","journal-title":"Clin Chim Acta"},{"key":"11473_CR68","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1073\/pnas.0510192103","volume":"103","author":"M van Pel","year":"2006","unstructured":"van Pel M, van Os R, Velders GA et al (2006) Serpina1 is a potent inhibitor of IL-8-induced hematopoietic stem cell mobilization. Proc Natl Acad Sci U S A 103:1469\u201374. https:\/\/doi.org\/10.1073\/pnas.0510192103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11473_CR69","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1084\/jem.20042299","volume":"201","author":"IG Winkler","year":"2005","unstructured":"Winkler IG, Hendy J, Coughlin P et al (2005) Serine protease inhibitors serpina1 and serpina3 are down-regulated in bone marrow during hematopoietic progenitor mobilization. J Exp Med 201:1077\u201388. https:\/\/doi.org\/10.1084\/jem.20042299","journal-title":"J Exp Med"},{"key":"11473_CR70","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.amjmed.2007.07.025","volume":"121","author":"T K\u00f6hnlein","year":"2008","unstructured":"K\u00f6hnlein T, Welte T (2008) Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation, diagnosis, and treatment. Am J Med 121:3\u20139. https:\/\/doi.org\/10.1016\/j.amjmed.2007.07.025","journal-title":"Am J Med"},{"key":"11473_CR71","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/glycob\/cwn015","volume":"18","author":"C Cederfur","year":"2008","unstructured":"Cederfur C, Salomonsson E, Nilsson J et al (2008) Different affinity of galectins for human serum glycoproteins: galectin-3 binds many protease inhibitors and acute phase proteins. Glycobiology 18:384\u2013394. https:\/\/doi.org\/10.1093\/glycob\/cwn015","journal-title":"Glycobiology"},{"key":"11473_CR72","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.exphem.2009.02.004","volume":"37","author":"HB Kuiperij","year":"2009","unstructured":"Kuiperij HB, van Pel M, de Rooij KE et al (2009) Serpina1 (\u03b11-AT) is synthesized in the osteoblastic stem cell niche. Exp Hematol 37:641\u2013647. https:\/\/doi.org\/10.1016\/j.exphem.2009.02.004","journal-title":"Exp Hematol"},{"key":"11473_CR73","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1182\/blood-2009-10-251660","volume":"115","author":"MJ Streetly","year":"2010","unstructured":"Streetly MJ, Maharaj L, Joel S et al (2010) GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood 115:3939\u201348. https:\/\/doi.org\/10.1182\/blood-2009-10-251660","journal-title":"Blood"},{"key":"11473_CR74","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.molimm.2011.05.021","volume":"48","author":"MA Toscano","year":"2011","unstructured":"Toscano MA, Campagna L, Molinero LL et al (2011) Nuclear factor (NF)-\u03baB controls expression of the immunoregulatory glycan-binding protein galectin-1. Mol Immunol 48:1940\u20139. https:\/\/doi.org\/10.1016\/j.molimm.2011.05.021","journal-title":"Mol Immunol"},{"key":"11473_CR75","doi-asserted-by":"publisher","first-page":"19592","DOI":"10.18632\/oncotarget.4285","volume":"6","author":"Y Harazono","year":"2015","unstructured":"Harazono Y, Kho DH, Balan V et al (2015) Extracellular galectin-3 programs multidrug resistance through Na+\/K+-ATPase and P-glycoprotein signaling. Oncotarget 6:19592\u2013604. https:\/\/doi.org\/10.18632\/oncotarget.4285","journal-title":"Oncotarget"},{"key":"11473_CR76","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41573-023-00636-2","volume":"22","author":"KV Mari\u00f1o","year":"2023","unstructured":"Mari\u00f1o KV, Cagnoni AJ, Croci DO, Rabinovich GA (2023) Targeting galectin-driven regulatory circuits in cancer and fibrosis. Nat Rev Drug Discov 22:295\u2013316. https:\/\/doi.org\/10.1038\/s41573-023-00636-2","journal-title":"Nat Rev Drug Discov"},{"key":"11473_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1104625","author":"DJ Laderach","year":"2023","unstructured":"Laderach DJ, Compagno D (2023) Inhibition of galectins in cancer: biological challenges for their clinical application. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.1104625","journal-title":"Front Immunol"},{"key":"11473_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1269391","author":"R Nehm\u00e9","year":"2023","unstructured":"Nehm\u00e9 R, St-Pierre Y (2023) Targeting intracellular galectins for cancer treatment. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1269391","journal-title":"Front Immunol"},{"key":"11473_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1145268","author":"N-I Kapetanakis","year":"2023","unstructured":"Kapetanakis N-I, Busson P (2023) Galectins as pivotal components in oncogenesis and immune exclusion in human malignancies. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1145268","journal-title":"Front Immunol"},{"key":"11473_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0721-7","volume":"37","author":"H Paz","year":"2018","unstructured":"Paz H, Joo EJ, Chou C-H et al (2018) Treatment of B-cell precursor acute lymphoblastic leukemia with the galectin-1 inhibitor PTX008. J Exp Clin Cancer Res 37:67. https:\/\/doi.org\/10.1186\/s13046-018-0721-7","journal-title":"J Exp Clin Cancer Res"},{"key":"11473_CR81","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.bbamcr.2018.04.005","volume":"1865","author":"PP Ruvolo","year":"2018","unstructured":"Ruvolo PP, Ruvolo VR, Burks JK et al (2018) Role of MSC-derived galectin 3 in the AML microenvironment. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1865:959\u2013969. https:\/\/doi.org\/10.1016\/j.bbamcr.2018.04.005","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11473-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11473-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11473-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T11:51:01Z","timestamp":1768909861000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11473-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11473"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11473-y","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"26 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"305"}}